Pacific Biosciences of California, Inc. (PACB)

Every figure this model derived for PACB, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 5,373,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 236,873,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 338,639,000 AssetsCurrent 2026-06-30
current liabilities 68,806,000 LiabilitiesCurrent 2026-06-30
equity -33,213,000 StockholdersEquity 2026-06-30
interest expense 7,329,000 InterestExpenseNonoperating 2026-06-30
ocf -118,050,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 159,271,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 34,294,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up PACB on one particular measure came for.

RatioValue
cash operating margin-55.9
current ratio6.43
current ratio reported4.92
deferred revenue growth8.34
dilution pct4.02
fcf margin-77.49
growth cv1.72
interest cover-18.15
operating margin-83.53
owner earnings margin-99.02
revenue growth2.02
revenue growth per share-1.92
rpo growth-15.37
rule of 40-81.51
sbc pct revenue21.53

What to be careful about

What this model itself distrusts about PACB's figures. Written by the derivation as it ran, not added afterwards.